FSGS Drug Development No Longer a ‘Graveyard’: What Comes After Sparsentan’s Approval

About this episode

This episode discusses the advancements in FSGS drug development following the approval of Sparsentan.

Topics covered

• FSGS
• drug development
• Sparsentan
• medicine

Keywords

• FSGS
• Sparsentan
• drug approval
• medical advancements

Mentioned in this episode

Products: Sparsentan

More episodes of HCPLive Podcasts

• Joint Ventures: EULAR 2026 Congress Preview · May 29, 2026 · 43 min
• Joint Ventures: The B-Cell Story, Part 2 — Ianalumab and the Next Chapter in Sjögren's and Lupus · May 28, 2026 · 36 min
• Joint Ventures: The B-Cell Story, Part 1 — From Rituximab to the Next Frontier · May 28, 2026 · 30 min
• Joint Ventures: GLP-1 Receptor Agonists — From Metabolic Drug to Immunomodulator? Part 2 · May 28, 2026 · 28 min
• Joint Ventures: GLP-1 Receptor Agonists — From Metabolic Drug to Immunomodulator? Part 1 · May 28, 2026 · 29 min
• Joint Ventures: Nipocalimab Advances and a Deucravacitinib Decision Looms · May 28, 2026 · 25 min